Viewing nowLyrica Capsule 300 mg (Pregabalin)
Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

MFDS item code 200511059 · Approved 2005.06.14 · Insurance code 073400220
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial-onset seizures)
This medication is used to treat peripheral and central neuropathic pain in adults. It is also effective as an adjunctive treatment for partial seizures in epilepsy patients, whether or not accompanied by secondary generalized symptoms. Additionally, it is utilized for the treatment of fibromyalgia, helping to relieve pain. It is used for various disorders related to pain and the nervous system.
The total daily dose of this medicine, as pregabalin, is administered orally in 2 divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If this dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day); based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Additional dose after hemodialysis: 25, 100, single dose b TID = Total daily dose administered in 3 divided dosesBID = Total daily dose administered in 2 divided dosesQD = Administered once dailya: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen.b: The additional dose refers to a single supplemental dose. 6. Patients with hepatic impairment No dose adjustment is required in patients with hepatic impairment. 8. Older adults (65 years or older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication should be carefully monitored during use, as it may lead to mental health issues such as suicidal thoughts, suicidal behavior, or depression. Patients with allergic reactions or specific genetic issues like lactose intolerance should not take this medication. Diabetic patients may experience weight gain after taking this medication, necessitating adjustment of their blood glucose control medications. If symptoms of angioedema occur, such as swelling of the face or around the mouth, the medication should be stopped immediately. Elderly patients may show symptoms such as dizziness, drowsiness, or confusion, so special care should be taken during the initial period of administration. This medication may cause temporary blurring of vision or changes in eyesight, so patients should consult with medical professionals if any abnormal symptoms occur. Abrupt discontinuation of this medication can lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so it should be tapered off gradually. Patients with a history of drug abuse may have a heightened risk of misuse of this medication, so they should use it cautiously. Patients with impaired renal function may require dose adjustments. Patients with heart disease should also take this medication cautiously. Caution is needed when combining this medication with opioid analgesics, as it could enhance central nervous system depression. Pregnant women or those planning to become pregnant should consult with a healthcare provider before use, as it may affect the fetus in early pregnancy. Breastfeeding women should consider cessation of breastfeeding or the medication, as it may be excreted in breast milk. Patients may experience dizziness and drowsiness while taking this medication, thus avoiding driving or operating hazardous machinery is advisable. In case of overdose, symptoms such as mental confusion, drowsiness, depression, or seizures may occur, requiring immediate emergency treatment. It is essential for patients needing special attention, such as children or the elderly, to consult with healthcare professionals before use. This medication should be kept out of the reach of children and should not be transferred to another container.
Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, swelling around the mouth, upper airway swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal ideation, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, orientation disturbances, irritability, depression, euphoria, decreased libido, insomnia, depersonalization, sexual arousal disorder, restlessness, anxiety, mood swings, emotional decline, emotional elevation, difficulty finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, inability to inhibit, apathy, dizziness, drowsiness, ataxia, coordination disturbances, balance disorders, amnesia, attention deficit, memory impairment, tremors, speech disorders, sensory abnormalities, sensory loss, sedation, hypersomnia, cognitive impairment, nystagmus, language disorders, myoclonic jerks, reflex reduction, motor abnormalities, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, activity tremors, syncope, confusion, motor retardation, olfactory abnormalities, loss of taste, writing disorders, blurred vision, diplopia, loss of indirect vision, visual disturbances, visual field defects, photopsia, dry eyes, eye swelling, decreased vision, eye pain, eye fatigue, increased tear production, eye irritation, mydriasis, changes in depth perception during vibration, strabismus, visual brightness, vertigo, auditory hypersensitivity, first-degree atrioventricular block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, breathing difficulty, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tightness, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, joint pain, back pain, limb pain, cervical cramps, joint swelling, myalgia, muscular spasms, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, reduced urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, gynecomastia, peripheral edema, edema, gait disturbances, falls, feeling intoxicated, sensory abnormalities, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), affective disorder, drowsiness, confused state, agitation, restlessness, seizures, shock, anaphylaxis-like symptoms, mucocutaneous syndrome, erythema multiforme
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it must be stored in a sealed container. Additionally, it is recommended to maintain a temperature between 15 to 30 degrees Celsius while storing the medication to preserve its effectiveness.
A hard capsule with a reddish-brown upper part and a white lower part containing white powder that is white or light yellow.
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Yuyoung Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.